Thromb Haemost 2004; 92(06): 1273-1276
DOI: 10.1160/TH04-05-0268
Rapid and Short Communication
Schattauer GmbH

Genetic variation in Fcγ receptor IIa protects against advanced peripheral atherosclerosis

The Rotterdam Study
Irene M. van der Meer
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Jacqueline C. M. Witteman
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Albert Hofman
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Cornelis Kluft
2   Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands
,
Moniek P. M. de Maat
2   Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands
› Author Affiliations
Financial support: Supported by the Netherlands Organization for Health Research and Development (ZON-MW), grant 980-10-005.
Further Information

Publication History

Received 02 May 2004

Accepted after revision 10 October 2004

Publication Date:
02 December 2017 (online)

Summary

Immune processes play a substantial role in atherosclerotic disease. The role in atherosclerosis of Fcγ receptor IIa (FcγRIIa), a receptor for immunoglobulin G and for the inflammatory mediator C-reactive protein, is not yet clear. Since the R/H131 polymorphism in the FcγRIIa gene strongly influences binding to FcγRIIa, we investigated the association of the R/H131 polymorphism with advanced peripheral atherosclerosis. Within the Rotterdam Study, a population-based cohort study, we determined FcγRIIa genotype in 430 subjects with advanced peripheral atherosclerosis as indicated by the ankle-arm index, and 411 controls. Heterozygous and homozygous carriers of the H131 allele were protected against advanced peripheral atherosclerosis (age- and gender-adjusted odds ratio (OR) 0.77 (0.54–1.12) and 0.65 (0.44–0.98), respectively, P trend=0.04). This effect was most pronounced in subjects with modestly elevated levels of inflammation as indicated by the leukocyte count (OR 0.52 (0.29–0.93) and 0.45 (0.23–0.86), for heterozygotes and H131 homozygotes, respectively; P trend=0.02). This is the first study showing that the H131 allele of FcγRIIa protects against advanced peripheral atherosclerosis.

 
  • References

  • 1 Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
  • 2 Ratcliffe NR, Kennedy SM, Morganelli PM. Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions. Immunol Lett 2001; 77: 169-74.
  • 3 van de Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991; 49: 511-24.
  • 4 Huang Y, Fleming AJ, Wu S. et al. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2000; 20: 2533-8.
  • 5 Danesh J, Whincup P, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. Br Med J 2000; 321: 199-204.
  • 6 Bharadwaj D, Stein MP, Volzer M. et al. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 1999; 190: 585-90.
  • 7 Torzewski M, Rist C, Mortensen RF. et al. Creactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-9.
  • 8 Zwaka TP, Hombach V, Torzewski J. Creactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
  • 9 Parren PW, Warmerdam PA, Boeije LC. et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90: 1537-46.
  • 10 Stein MP, Edberg JC, Kimberly RP. et al. Creactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allelespecific. J Clin Invest 2000; 105: 369-76.
  • 11 Hofman A, Grobbee DE, de Jong PT. et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 07: 403-22.
  • 12 Meijer WT, Hoes AW, Rutgers D. et al. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-92.
  • 13 Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol 2001; 31: 3475-83.
  • 14 Newman AB, Siscovick DS, Manolio TA. et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837-45.